High‐molecular‐weight kininogen cleavage correlates with disease states in the bradykinin‐mediated angioedema due to hereditary C1‐inhibitor deficiency

The inherited deficiency of C1‐inhibitor (C1‐INH), which can be quantitative (type I) or qualitative (type II), is characterized by recurrent attacks of oedema, and it is known as hereditary angioedema due to C1‐INH deficiency (HAE‐C1‐INH). The frequency of symptoms varies widely among patients and in the same patient during life.

[1]  A. Gompel,et al.  Hereditary angioedema with C1 inhibitor deficiency: clinical presentation and quality of life of 193 French patients. , 2013, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[2]  S. Cichon,et al.  Enzymatic Assays for the Diagnosis of Bradykinin-Dependent Angioedema , 2013, PloS one.

[3]  A. Tordai,et al.  Less severe clinical manifestations in patients with hereditary angioedema with missense C1INH gene mutations. , 2013, The Journal of allergy and clinical immunology.

[4]  G. Casazza,et al.  Long-term prophylaxis in hereditary angio-oedema: a systematic review , 2012, BMJ Open.

[5]  M. Riedl.  Hereditary angioedema therapies in the United States: movement toward an international treatment consensus. , 2012, Clinical therapeutics.

[6]  W. V. van Heerde,et al.  Alterations of coagulation and fibrinolysis in patients with angioedema due to C1‐inhibitor deficiency , 2012, Clinical and experimental immunology.

[7]  M. Triggiani,et al.  Evidence‐based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: consensus report of an International Working Group , 2012, Allergy.

[8]  L. Bergamaschini,et al.  Interaction of C1 inhibitor with thrombin on the endothelial surface , 2011, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[9]  A. Kaplan.  Enzymatic pathways in the pathogenesis of hereditary angioedema: the role of C1 inhibitor therapy. , 2010, The Journal of allergy and clinical immunology.

[10]  M. Zilberberg,et al.  The burden of hospitalizations and emergency department visits with hereditary angioedema and angioedema in the United States, 2007. , 2010, Allergy and asthma proceedings.

[11]  W. Lumry,et al.  The humanistic burden of hereditary angioedema: Impact on health-related quality of life, productivity, and depression. , 2010, Allergy and asthma proceedings.

[12]  A. Sheffer,et al.  Ecallantide for the treatment of acute attacks in hereditary angioedema. , 2010, The New England journal of medicine.

[13]  William H. Yang,et al.  Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. , 2010, The New England journal of medicine.

[14]  A. Kaplan,et al.  The plasma bradykinin-forming pathways and its interrelationships with complement. , 2010, Molecular immunology.

[15]  A. Kaplan,et al.  Treatment of episodes of hereditary angioedema with C1 inhibitor: serial assessment of observed abnormalities of the plasma bradykinin-forming pathway and fibrinolysis. , 2010, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[16]  J. Bernstein,et al.  Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks. , 2009, The Journal of allergy and clinical immunology.

[17]  A. Bellatorre,et al.  Plasma biomarkers of acute attacks in patients with angioedema due to C1‐inhibitor deficiency , 2009, Allergy.

[18]  A. Tordai,et al.  Mutation screening of C1 inhibitor gene in 108 unrelated families with hereditary angioedema: functional and structural correlates. , 2008, Molecular immunology.

[19]  A. Kaplan,et al.  Studies of the mechanisms of bradykinin generation in hereditary angioedema plasma. , 2008, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[20]  M. Cicardi,et al.  Acquired deficiency of the inhibitor of the first complement component: presentation, diagnosis, course, and conventional management. , 2006, Immunology and allergy clinics of North America.

[21]  Andrea Zanichelli,et al.  C1 inhibitor: molecular and clinical aspects , 2005, Springer Seminars in Immunopathology.

[22]  M. López-Trascasa,et al.  Hereditary angioedema: The mutation spectrum of SERPING1/C1NH in a large Spanish cohort , 2005, Human mutation.

[23]  F. Rosen,et al.  Deficiencies of C1 inhibitor. , 2005, Best practice & research. Clinical gastroenterology.

[24]  A. Tordai,et al.  HAEdb: A novel interactive, locus‐specific mutation database for the C1 inhibitor gene , 2005, Human mutation.

[25]  A. Tordai,et al.  Hereditary and acquired angioedema: Problems and progress: Proceedings of the third C1 esterase inhibitor deficiency workshop and beyond , 2004, Journal of Allergy and Clinical Immunology.

[26]  A. Tordai,et al.  Mutation screening of the C1 inhibitor gene among Hungarian patients with hereditary angioedema , 2003, Human mutation.

[27]  J. Whisstock,et al.  The Serpins Are an Expanding Superfamily of Structurally Similar but Functionally Diverse Proteins , 2001, The Journal of Biological Chemistry.

[28]  S. Choquet,et al.  Frequent de novo mutations and exon deletions in the C1inhibitor gene of patients with angioedema. , 2000, The Journal of allergy and clinical immunology.

[29]  B. Zuraw,et al.  Detection of C1 inhibitor mutations in patients with hereditary angioedema. , 2000, The Journal of allergy and clinical immunology.

[30]  M. Cicardi,et al.  Local bradykinin generation in hereditary angioedema. , 1999, The Journal of allergy and clinical immunology.

[31]  W. Müller-Esterl,et al.  Parallel Reduction of Plasma Levels of High and Low Molecular Weight Kininogen in Patients with Cirrhosis , 1999, Thrombosis and Haemostasis.

[32]  M. Cicardi,et al.  Plasma bradykinin in angio-oedema , 1998, The Lancet.

[33]  P. Mannucci,et al.  Activation of the coagulation cascade in C1-inhibitor deficiencies. , 1997, Blood.

[34]  W. Müller-Esterl,et al.  Rapid Direct Determination of Low and High Molecular Weight Kininogen in Human Plasma by Particle Concentration Fluorescence Immunoassay (PCFIA) , 1997, Thrombosis and Haemostasis.

[35]  E. Verpy,et al.  Exhaustive mutation scanning by fluorescence-assisted mismatch analysis discloses new genotype-phenotype correlations in angiodema. , 1996, American journal of human genetics.

[36]  M. Cicardi,et al.  Activation of factor XII and cleavage of high molecular weight kininogen during acute attacks in hereditary and acquired C1-inhibitor deficiencies. , 1996, Immunopharmacology.

[37]  M. Cicardi,et al.  Activation of the contact system and fibrinolysis in autoimmune acquired angioedema: a rationale for prophylactic use of tranexamic acid. , 1994, The Journal of allergy and clinical immunology.

[38]  A. Davis,et al.  Hereditary angioneurotic oedema: characterization of plasma kinin and vascular permeability‐enhancing activities , 1994, Clinical and experimental immunology.

[39]  A. Eerenberg,et al.  Generation of plasmin during acute attacks of hereditary angioedema. , 1993, The Journal of laboratory and clinical medicine.

[40]  A. Cardin,et al.  Mechanism of enhanced kinin release from high molecular weight kininogen by plasma kallikrein after its exposure to plasmin. , 1992, The Journal of laboratory and clinical medicine.

[41]  M. Cicardi,et al.  Hereditary and Acquired C1‐Inhibitor Deficiency: Biological and Clinical Characteristics in 235 Patients , 1992, Medicine.

[42]  A. Schmaier,et al.  Alpha 2-macroglobulin-kallikrein complexes detect contact system activation in hereditary angioedema and human sepsis. , 1991, Blood.

[43]  E. Hack,et al.  Plasma levels of C1- inhibitor complexes and cleaved C1- inhibitor in patients with hereditary angioneurotic edema. , 1990, The Journal of clinical investigation.

[44]  C. Kluft,et al.  Haemostasis Contact System and Fibrinolysis in Hereditary Angioedema (Cl-Inhibitor Deficiency) , 1988, Journal of clinical chemistry and clinical biochemistry. Zeitschrift fur klinische Chemie und klinische Biochemie.

[45]  D. Stoppa-Lyonnet,et al.  Altered C1 inhibitor genes in type I hereditary angioedema. , 1987, The New England journal of medicine.

[46]  F. Rosen,et al.  Molecular basis for the deficiency of complement 1 inhibitor in type I hereditary angioneurotic edema. , 1987, The Journal of clinical investigation.

[47]  B. Lämmle,et al.  Detection of in vitro and in vivo cleavage of high molecular weight kininogen in human plasma by immunoblotting with monoclonal antibodies. , 1986, Blood.

[48]  A. Kaplan,et al.  Kinin formation in hereditary angioedema plasma: evidence against kinin derivation from C2 and in support of "spontaneous" formation of bradykinin. , 1983, The Journal of allergy and clinical immunology.

[49]  R. Colman,et al.  Prekallikrein activation and high-molecular-weight kininogen consumption in hereditary angioedema. , 1983, The New England journal of medicine.

[50]  J. Dunn,et al.  Mechanisms of activation of the classical pathway of complement by Hageman factor fragment. , 1983, The Journal of clinical investigation.

[51]  N. Müller,et al.  Complement, coagulation and fibrinolytic parameters in hereditary angioedema (HAE). , 1982, Clinical and Experimental Immunology.

[52]  R. Harrison,et al.  Complexes between C1-inhibitor, kallikrein, high molecular weight kininogen, plasma thromboplastin antecedent, and plasmin in normal human plasma and hereditary angioneurotic edema plasmas containing dysmorphic C1-inhibitors: role of cold activation. , 1982, Blood.

[53]  M. Gallimore,et al.  Simple chromogenic peptide substrate assays for determining prekallikrein, kallikrein inhibition and kallikrein "like" activity in human plasma. , 1982, Thrombosis research.

[54]  M. Silverberg,et al.  Activation of the classical pathway of complement by Hageman factor fragment , 1981, The Journal of experimental medicine.

[55]  C. Cochrane,et al.  Detection of active kallikrein in induced blister fluids of hereditary angioedema patients , 1980, The Journal of experimental medicine.

[56]  C. Laurell,et al.  A comparison of plasma protein changes induced by danazol, pregnancy, and estrogens. , 1979, The Journal of clinical endocrinology and metabolism.

[57]  V. Donaldson.  MECHANISMS OF ACTIVATION OF C'1 ESTERASE IN HEREDITARY ANGIONEUROTIC EDEMA PLASMA IN VITRO , 1968, The Journal of experimental medicine.

[58]  Austen Kf,et al.  Detection of Hereditary Angioneurotic Edema by Demonstration of a Reduction in the Second Component of Human Complement , 1965 .

[59]  A. Sheffer,et al.  DETECTION OF HEREDITARY ANGIONEUROTIC EDEMA BY DEMONSTRATION OF A REDUCTION IN THE SECOND COMPONENT OF HUMAN COMPLEMENT. , 1965, The New England journal of medicine.

[60]  K. Austen,et al.  THE MEASUREMENT OF SECOND COMPONENT OF HUMAN COMPLEMENT (C'2HU) BY ITS INTERACTION WITH EAC'1AGP,4GP CELLS. , 1964, Journal of immunology.

[61]  R. R. Evans,et al.  A BIOCHEMICAL ABNORMALITY IN HEREDIATRY ANGIONEUROTIC EDEMA: ABSENCE OF SERUM INHIBITOR OF C' 1-ESTERASE. , 1963, The American journal of medicine.

[62]  E. Becker,et al.  Hereditary angioneurotic edema: II. Deficiency of inhibitor for serum globulin permeability factor and/or plasma kallikrein , 1962 .